None

Denosumab (Denosumab) is a targeted drug, specifically a monoclonal antibody. Its mechanism of action is by targeting a protein in the body called RANKL (receptor-activated nuclear factor kappa B ligand) to inhibit the bone resorption process, thereby increasing bone density and reducing the risk of fractures.

Denosumab is used to treat bone-related diseases such as osteoporosis and cancer bone metastases. RANKL is an important molecule that plays a key role in the bone resorption process, activating bone cells (osteoclasts), leading to osteoporosis and fractures. Desosumab inhibits the bone resorption process by binding to RANKL and preventing it from binding to bone cells, increasing bone density and reducing the risk of fractures.

This medication is usually given as a subcutaneous injection every six months. Although it is a targeted drug that can powerfully affect the progression of bone-related diseases, it is also accompanied by some side effects, such as skin reactions, hypocalcemia, osteonecrosis of the jaw, etc., so patients need to consult their doctor before use to understand the suitability and risks of the drug.

The generic drug Desosomet is already on the market in China and has been included in medical insurance. Patients can purchase it domestically at a price of about 1,600 yuan. Please consult the local hospital pharmacy or medical insurance bureau for specific prices and reimbursement policies. There are only denosumab original drugs available abroad, mainly the Turkish version of the American Amgen original drug. The price is about 1,300 yuan, and the ingredients and efficacy are consistent with the domestic original drug.